Fluidigm Summer 2011 eNewsletter
Villebon sur Yvette, France & South San Francisco CA, USA — Fluidigm has announced its Summer 2011 eNewsletter that researchers from the National Cancer Centre, Singapore, KK Women’s & Children’s Hospital, and the Singapore General Hospital report upon their evaluation of nanofluidics technology using DNA extracted from peripheral blood and buccal wash samples for high-throughput SNP Genotyping in a clinical setting.
Another independent paper presented in the newsletter discusses how single-cell gene expression profiling reveals qualitatively distinct CD8 T cells elicited by different gene-based vaccines.
The paper describes how researchers at the National Cancer Institute, Rockville, MD, USA gained an understanding of the mechanism of protective immunity mediated by CDS T cells, how the process is dependent upon the definition of heterogeneity, and also how immune responses are generated by different vaccines.
An abstract of a new poster from Fluidigm in conjunction with BD Biosciences describes a protocol where flow cytometry is paired with gene expression analysis to discriminate variation in phenotype and gene expression at the single-cell level and discusses how they may be pivotal in the differentiation of stem cells.
Complimenting the poster and independent customer research publications, the Summer 2011 newsletter also provides an introduction to Fluidigm’s new assays for gene expression, genotyping and and target-specific primers for targeted resequencing as well as a new 192.24 Dynamic Array™ Integrated Fluidic Circuit (IFC) for high sample throughput SNP genotyping.
The Summer 2011 edition of the Fluidigm Corporation Community Newsletter is now available free to download from www.fluidigm.com/home/fluidigm/email/Q2_2011.html
Fluidigm (NASDAQ:FLDM) develops, manufactures and markets microfluidic systems for growth markets in the life science and agricultural biotechnology, or Ag-Bio, industries. Fluidigm’s proprietary microfluidic systems consist of instruments and consumables, including chips and reagents. These systems are designed to significantly simplify experimental workflow, increase throughput and reduce costs, while providing the excellent data quality demanded by customers. Fluidigm actively markets three microfluidic systems including eight different commercial chips to leading pharmaceutical and biotechnology companies, academic institutions and Ag-Bio companies.
For more information, please visit www.fluidigm.com.
15 Avenue de Norvege
91140 Villebon sur Yvette
7000 Shoreline Court Suite 100,
South San Francisco CA 94080 USA